Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the β-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 3, 2009, Pages 303-309

  Zhang, Meili ^a,d   Yao, Zhengsheng ^a,c   Garmestani, Kayhan ^a,e   Yu, Sarah ^c   Goldman, Carolyn K ^a   Paik, Chang H ^c   Brechbiel, Martin W ^b   Carrasquillo, Jorge A ^c,f   Waldmann, Thomas A ^a,b  

^a Metabolism Branch   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Pathology/Histotechnology Laboratory   (United States)

^e SAIC FREDERICK INC   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

emitter; CD25; Lymphoma; Monoclonal antibody; Radioimmunotherapy

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7G7 B6 Y 90; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG DISTRIBUTION; IMMUNOREACTIVITY; ISOTOPE LABELING; LYMPHOMA; MOUSE; NONHUMAN; POSITRON; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; ENDOCYTOSIS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KAPLAN-MEIERS ESTIMATE; LYMPHOMA; MAXIMUM TOLERATED DOSE; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 67651046563     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0577     Document Type: Article

References (30)

1. Waldmann TA. Effective cancer therapy through im-munomodulation. Annu Rev Med 2006;57:65.
2. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004;3:488.
3. Waldmann T. ABCs of radioisotopes used for radioimmunotherapy: Alpha- and beta-emitters. Leuk Lymph 2003;44(Suppl 3):S107.
4. Waldmann TA. Immunotherapy: Past, present and future. Nat Med 2003;9:269.
5. Janik JE, Morris JC, Pittaluga S, et al. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. Blood 2004;104:3355.
6. Morris JC, Waldmann TA. Advances in interleukin-2-receptor-targeted treatment. Ann Rheum Dis 2000;59(Suppl 1):i109.
7. Waldmann TA, White JD, Goldman CK, et al. The inter-leukin-2 receptor: A target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 1993;82:1701.
8. Rubin LA, Kurman CC, Biddison WE, et al. A monoclonal antibody, 7G7/B6, binds to an epitope on the human inter-leukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac. Hybridoma 1985;4:91.
9. Waldmann TA, White JD, Carrasquillo JA, et al. Radio-immunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 1995;86:4063.
10. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. NEJM 2002;346:235.
11. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEJM 2001;344:783.
12. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T- cell leukemia. Cancer Res 2002;62:1083.
13. Wu K, Wang C, D'Amico M, et al. Flavopiridol and trastu-zumab synergistically inhibit proliferation of breast cancer cells: Association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther 2002;1:695.
14. Zhang M, Yao Z, Garmestani K, et al. Pretargeting radio-immunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood 2002;100:208.
15. Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci U S A 2003;100:1891.
16. Zhang M, Zhang Z, Goldman CK, et al. Combination therapy for adult T-cell leukemia-xenografted mice: Flavopiridol and anti-CD25 monoclonal antibody. Blood 2005; 105:1231.
17. 211At-7G7/B6 and its combination with unmodified anti-Tac (da-clizumab) directed toward CD25. Blood 2006;108:1007.
18. Perera LP, Marques LR, O'Brien AD. Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay. J Clin Microbiol 1988;26:2127.
19. Kobayashi H, Wu C, Yoo TM, et al. Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. J Nucl Med 1998;39:829.
20. 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 2002;29:431.
21. Yao Z, Sakahara H, Zhang M, et al. Radioimmunoimaging of colon cancer xenografts with anti-Tn monoclonal antibody. Nucl Med Biol 1995;22:199.
22. Yao Z, Garmestani K, Wong KJ, et al. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J Nucl Med 2001;42:1538.
23. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha-particle immunotherapy for myeloid leukemia. Blood 2002; 100:1233.
24. Macklis RM, Kinsey BM, Kassis AI, et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science 1988;240:1024.
25. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294:1537.
26. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998;25:1341.
27. 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res 2006;66:8227.
28. Yao Z, Zhang M, Axworthy DB, et al. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibodystreptavidin and 90Y-labeled 1,4,7,10-tetraazacyclododecaneN,N′ ,N,N′-tetraacetic acid (DOTA)-biotin. Cancer Res 2002;62:5755.
29. Phillips KE, Herring B, Wilson LA, et al. IL-2R alpha-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2R alpha interaction. Cancer Res 2000;60:6977.
30. Zhang M, Zhang Z, Garmestani K, et al. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia. Cancer Res 2004;64:5825.